MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
28.43
+1.41
+5.22%
After Hours: 28.99 +0.56 +1.97% 18:16 06/26 EDT
OPEN
27.02
PREV CLOSE
27.02
HIGH
29.95
LOW
26.71
VOLUME
3.55M
TURNOVER
--
52 WEEK HIGH
53.65
52 WEEK LOW
9.83
MARKET CAP
1.57B
P/E (TTM)
-11.2755
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics CEO Jason V. Coloma sells USD 723,021 in common shares
PUBT · 3d ago
Mizuho Securities Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks · 4d ago
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
TipRanks · 5d ago
Weekly Report: what happened at MAZE last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at MAZE last week (0608-0612)?
Weekly Report · 06/15 09:24
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
TipRanks · 06/10 22:07
Weekly Report: what happened at MAZE last week (0601-0605)?
Weekly Report · 06/08 09:23
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.